Articles from Chemify

Lee Cronin, CEO and founder of Chemify, the deep-tech pioneer of Chemputation – a technological breakthrough that integrates AI- and ML-driven molecular discovery and automated, robotic synthesis – has published three peer-reviewed research papers in close succession, constituting a technological tour de force that validates Chemputation as a new paradigm for how small molecule-drugs and materials are discovered, designed and manufactured.

Chemify, the deep-tech pioneer of Chemputation – a technological breakthrough that combines ML-based molecular discovery and automated, robotic synthesis – today announced a collaboration with Sanacor Inc. – a biotechnology company developing therapies that target mitochondrial dysfunction in cardiometabolic diseases – to discover and develop orally available small-molecule inhibitors for the treatment of cardiometabolic diseases with a first focus on diabetic cardiovascular disease.

Chemify, the deep-tech pioneer fusing chemistry, robotics, computation, and Chemputation—Chemify’s purpose-built AI to digitize molecule creation—has received additional grant funding of $1.6 million from the Gates Foundation to continue the discovery of small molecules for tuberculosis (TB). Building on a successful collaboration with Lgenia, the expanded project will leverage Chemify’s automated platform to design and synthesize new drug leads addressing one of the world’s most urgent infectious diseases.

Chemify, the deep-tech pioneer fusing chemistry, robotics, computation, and Chemputation—Chemify’s purpose-built AI to digitize molecule creation—has raised over $50 million in Series B funding to help accelerate its mission of becoming the global leader in digital chemistry, molecular design and manufacturing. The oversubscribed round was co-led by Wing Venture Capital and Insight Partners, with participation from a syndicate of world-class investors including 8VC and existing backers Triatomic Capital, Blueyard, Rockspring and Eos.

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Michael Bell has joined as Chief Technology Officer. As a well-known technology veteran in the digital computing industry who helped lead the creation of the Apple iPhone and the launch of Intel’s mobile devices, Mr. Bell will help accelerate the capabilities of Chemify’s digital chemistry platform and the world’s first chemical programming language.

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Dr. Alastair Leighton has joined as Chief Operating Officer (COO). With almost three decades in the biopharma industry working at leading global pharmaceutical companies, Dr. Leighton brings a wealth of experience in manufacturing, supply chain operations and commercial strategy.

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that it has been awarded a grant from the Bill & Melinda Gates Foundation to discover new drug leads for treating tuberculosis (TB) and malaria. By leveraging the company’s proprietary Chemputation technology and workflow, Chemify aims to deliver unmatched drug design and discovery outcomes and potential drug candidates to positively impact the lives of patients worldwide.

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Kevin McGowan, PhD, MBA, will join the company as Chief Business Officer (CBO). As an expert in pharmaceutical business development, platform technology strategy, sales and marketing, McGowan will help Chemify scale its commercialization and operations and further expand into U.S. markets.

Chemify and Prepaire™ Labs today announced to expand their partnership with an additional program to tackle the ongoing Opioid crisis and develop a novel class of digitally discovered non-addictive Opioids as pain modulators, as well as drugs tackling Opioid addiction directly by combining Chemify's breakthrough programmable chemistry platform with Prepaire’s integrated novel open collaboration drug discovery platform. The project, named Toxifree, comes in response to the FDA’s Center for Drug Evaluation and Research (CDER) requesting drugmakers and researchers to develop treatments for stimulant use disorder, hoping to address a major gap in the addiction crisis response.

Chemify, a pioneering company operating its proprietary molecular design, discovery, and chemical manufacturing technology to provide pharmaceutical, biotechnology, and industrial partners with better molecules, today announced funding of $43 million including a Series A led by Triatomic Capital, joined by new investors including Hong-Kong based Horizon Ventures, US-based Rocketship Ventures, Possible Ventures, Alix Ventures, Scotland-based Eos, and the UK Government Innovation Accelerators program. Existing investor BlueYard Capital also participated in the round.